HK Stock Market Move | HIGHTIDE-B (02511) rose nearly 8% with first half-year losses narrowing by 42.96% year-on-year.

HIGHTIDE-B (02511) rose nearly 8%, as of the time of writing, it increased by 7.94% to 3.4 Hong Kong dollars, with a transaction amount of 5.8183 million Hong Kong dollars. On the news front, Junshengtai Pharmaceutical released its interim performance for the six months ending on June 30, 2025. Other income was 10.542 million yuan, a decrease of 69.96% year-on-year; shareholders' attributable loss was 120 million yuan, a decrease of 42.96% year-on-year; basic loss per share was 0.27 yuan. The announcement stated that the decrease in other income was mainly due to a reduction in government subsidies of around 19.1 million yuan. The company's core product HTD1801 is a globally pioneering targeted oral anti-inflammatory and metabolic regulator for the gut-liver system. Currently, HTD1801 is being developed globally for the treatment of CKM-related diseases, including type 2 diabetes (T2DM), metabolic associated fatty liver disease (MASH), chronic kidney disease (CKD), obesity, primary sclerosing cholangitis (PSC), and severe hypertriglyceridemia (SHTG).